Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Lipocine Inc.
Posted on: 25 Sep 18
Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference

PR Newswire

SALT LAKE CITY, Sept. 25, 2018

SALT LAKE CITY, Sept. 25, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference, being held October 2, 2018, at the Sofitel Hotel in New York City.

Presentation Details

Date:

Tuesday, October 2nd    

Time:

12:00 p.m. Eastern Time

Location:

Sofitel New York Hotel, Madeleine Room

Webcast:

http://wsw.com/webcast/ladenburg4/lpcn/

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes four development programs TLANDO, LPCN 1111, LPCN 1107 and LPCN 1144. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO received a Complete Response Letter from the FDA on May 8, 2018. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. LPCN 1144, an oral androgen, is being developed as a treatment of non-alcoholic steatohepatitis ("NASH") and is currently being studied in two proof-of-concept clinical studies. For more information, please visit www.lipocine.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference-300716048.html

SOURCE Lipocine Inc.

PR Newswire
www.prnewswire.com

Last updated on: 25/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.